The European Medicines Agency experience with biomarker qualification.
Since the launch of the qualification process in 2009, the CHMP reviewed/is reviewing 48 requests for qualification advice or opinion (as of Sept 2013) related to biomarkers (BM) or other novel drug development tools (e.g. patient reported outcome measures, modeling, and statistical methods). The qualification opinions are available on the EMA website (Qualification of novel methodologies for medicine development, http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000319.jsp&mid=WC0b01ac0580022bb0#section2 , 2013). Also there is a trend of increasing numbers of qualification requests to CHMP, indicative of the pace that targeted drug development and personalized medicine is gaining and the need to bring the new tools from research to drug development and clinical use. This chapter will focus on the regulatory experience gained so far from the CHMP qualification procedure. Basic qualification principles will be presented. Through qualification examples, we will elaborate on common grounds and divergences between the different stakeholders.
European Medicines Agency, 30 Churchill Place, Canary Warf, London, E14 5EU, UK, efthymios.manolis@ema.europa.eu.
Efthymios
E
Manolis
Armin
A
Koch
Dieter
D
Deforce
Spiros
S
Vamvakas
D000818:Animals; D015415:Biomarkers / Q000032:analysis*; D019963:Clinical Chemistry Tests / Q000379:methods*; D005060:Europe; D006077:Government Agencies; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000378:metabolism; D040901:Proteomics
D015415:Biomarkers